 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Statens Serum Institut |
| Street 1: | Artillerivej 5 |
| Street 2: | |
| City: | Copenhagen |
| Province: | |
| Post Code: | 2300 |
| Country: | Denmark |
| Phone: | 4532688401 |
| Organization Email: | serum@ssi.dk |
| Web Site: | http://www.ssi.dk |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Countries |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Governmental Organization |
| Organization Type - Secondary: | None |
| Organization Description: | |
| Statens Serum Institut (SSI) was inaugurated on 9 September 1902 and is one of the oldest institutions of its kind. SSI is an enterprise under the Danish Ministry of the Interior and Health and the Institute’s duties are partly integrated in the national Danish health services. SSI’s goal is to prevent and control infectious diseases and congenital disorders. During the years SSI has developed into a national and international biotechnological institute performing research and development, production and services. Today SSI holds a prominent position in the international cooperation in the fight against infectious diseases especially tuberculosis and provides internationally recognized research within this field. In 2005 SSI’s TB subunit vaccine candidate will be tested in humans. SSI maintains a considerable production of BCG vaccine, which is prequalified by WHO. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 26 - 50 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Involvement in TB control provision |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Information on developments within the TB world |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| International Reference Laboratory of Mycobacteriology Purpose The International Reference Laboratory of Mycobacteriology is the National Tuberculosis (TB) Reference Laboratory and carries out selected reference functions for Iceland and Lithuania. Laboratory based surveillance of human TB for Denmark, Greenland and the Faroe Islands. Diagnostics in human specimens from Denmark, Greenland and the Faroe Islands Research and development within the key areas of the laboratory. Reference functions for Iceland and Lithuania. Tasks Diagnostics and surveillance: Diagnosis of active tuberculous disease and disease caused by non-tuberculous mycobacteria NTM (”atypical mycobacteria” or Mycobacteria other than M. tuberculosis ”MOTT”) by means of microscopy, PCR, culture, and identification. Detection of drug resistance by the proportion method as well as detection of mutations for rifampin and/or isoniazide by array techniques. Detection of M. tuberculosis infection by interferon-g release assays (IGRA) in ELISA after antigen stimulation of blood. Quantitative measurement of concentrations of first line anti-tuberculous drugs. Contribute to TB surveillance by annual making up of laboratory data regarding disease localisation, infectiousness, drug resistance and transmission of M. tuberculosis complex in collaboration with the Department of Epidemiology. Carry out surveillance of resistant M. tuberculosis incl. multi-drug resistant (MDR) and extensively resistant (XDR) M. tuberculosis. Participate in annual national reporting in Epi-News. Participate in annual international reporting to ECDC and WHO. Carry out genotypning of isolated M. tuberculosis stains from Denmark (introduced 1992). Carry out national reference functions in the form of i form guidance and making profiency panels available for microscopy in local microbiology departments in Denmark on request. Give guidance on preventive measures, treatment, transmission, contact tracing, and interpretation of results. Research and development: Resistance, recurrence and treatment outcome of TB in Denmark. TB epidemiologi in Denmark based on genotypning (1992-2006). Hetero resistance in M. tuberculosis. Pharmaco kinetics of anti tuberculous drugs i selected patient populations. Genotypning of M. tuberculosis stains by MIRU VNTR 24 loci. Collaborative actions: Participate in the Danish TB Expert Panel. Participate in the Baltic-Nordic TB Network. Reference functions for Island and Litauen. Participate in the management group of the European TB Reference Laboratory Network. Participate in ECDC´s and WHO´s coordination group for surveillance of TB in the Europe-region. Education of health staff and supervision of Master- and PhD- students. |
|
Geographical Reach | |
| Which country is your headquarters located in: | Denmark |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Denmark |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Laboratory Strengthening: International Reference Laboratory of Mycobacteriology Purpose The International Reference Laboratory of Mycobacteriology is the National Tuberculosis (TB) Reference Laboratory and carries out selected reference functions for Iceland and Lithuania. Laboratory based surveillance of human TB for Denmark, Greenland and the Faroe Islands. Diagnostics in human specimens from Denmark, Greenland and the Faroe Islands Research and development within the key areas of the laboratory. Reference functions for Iceland and Lithuania. Tasks Diagnostics and surveillance: Diagnosis of active tuberculous disease and disease caused by non-tuberculous mycobacteria NTM (”atypical mycobacteria” or Mycobacteria other than M. tuberculosis ”MOTT”) by means of microscopy, PCR, culture, and identification. Detection of drug resistance by the proportion method as well as detection of mutations for rifampin and/or isoniazide by array techniques. Detection of M. tuberculosis infection by interferon-g release assays (IGRA) in ELISA after antigen stimulation of blood. Quantitative measurement of concentrations of first line anti-tuberculous drugs. Contribute to TB surveillance by annual making up of laboratory data regarding disease localisation, infectiousness, drug resistance and transmission of M. tuberculosis complex in collaboration with the Department of Epidemiology. Carry out surveillance of resistant M. tuberculosis incl. multi-drug resistant (MDR) and extensively resistant (XDR) M. tuberculosis. Participate in annual national reporting in Epi-News. Participate in annual international reporting to ECDC and WHO. Carry out genotypning of isolated M. tuberculosis stains from Denmark (introduced 1992). Carry out national reference functions in the form of i form guidance and making profiency panels available for microscopy in local microbiology departments in Denmark on request. Give guidance on preventive measures, treatment, transmission, contact tracing, and interpretation of results. Research and development: Resistance, recurrence and treatment outcome of TB in Denmark. TB epidemiologi in Denmark based on genotypning (1992-2006). Hetero resistance in M. tuberculosis. Pharmaco kinetics of anti tuberculous drugs i selected patient populations. Genotypning of M. tuberculosis stains by MIRU VNTR 24 loci. Collaborative actions: Participate in the Danish TB Expert Panel. Participate in the Baltic-Nordic TB Network. Reference functions for Island and Litauen. Participate in the management group of the European TB Reference Laboratory Network. Participate in ECDC´s and WHO´s coordination group for surveillance of TB in the Europe-region. Education of health staff and supervision of Master- and PhD- students. New Diagnostics: Researchers at SSI have pioneered work both on novel diagnostic assays (the IGRA assays) and in identification of several key antigens that are used in tuberculosis in-vitro diagnostics ( e.g. IGRAs) New TB Vaccines: At SSI we investigate the interactions between the host and the pathogen and identify the immunological mechanisms that combat the bacteria. We study the disease process and the immune response with cutting edge techniques applied to samples from TB patients and in advanced animal models of the disease. The information we obtain is translated into the design of novel vaccines designed for maximum activity against the different stages of the disease. Our goal is to provide vaccines that protect individuals before they acquire the infection, as well as vaccines that can protect the numerous people already infected with TB from developing the disease. We have developed three different vaccines and are currently evaluating them in clinical trials in Africa and Europe. |
|
Declaration | |
| Declaration of interests: An apparent conflict of interest Statens Serum Institut (SSI) is an enterprise under the Danish Ministry of the Interior and Health. The enterprise consists of production and sales of BCG VACCINE SSI and TUBERCULIN PPD RT 23 SSI to UNICEF and countries around the world. This could be an apparent conflict of interest. | |
| Application date: | |
| Last updated: | October 21, 2013 |